Pharmalot… Pharmalittle… Good Morning
Make a commentBy Ed Silverman // October 3rd, 2011 // 7:05 am
Hello, everyone, and nice to see you again after the long break. We hope your weekend was relaxing. We tried to use the time wisely. Now, though, the time has come to resume that routine of meetings and deadlines. And there is much to do. So, yes, we are brewing a cup of stimulation to help the synapses and invite you to do the same. Meanwhile, here are some tidbits as we play catch up. Hope your day goes well and stay in touch…
PPD Is Bought By Private Equity Firms For $3.8 Billion (Associated Press)
Abbott Cuts 160 Jobs From Diagnostic Division (Bloomberg News)
Why Universities And Biotechs Need Each Other (Xconomy)
Prescription Drug Shortages Are Worse This Year (HealthDay)
AstraZeneca Settles Seroquel XR Patent Litigation (Pharma Times)
Glaxo Ordered To Pay Pharmacist For Recalled Med (New Zealand Herald)
Glaxo Eyes More Acquisitions In India (Agence France-Presse)
Bayer And J&J’s Xarelto Helped ACS Patients In Study (Bloomberg News)
Michigan Supreme Court Turns Down State AG Vioxx Appeal (Associated Press)
Just 21 Days Until Lilly Loses The Zyprexa Patent (Indianapolis Star)
Pfizer Fungal Meds Failed To Meet Study Goal (Associated Press)
Indian Regulator May Get Added Authority Over Prices (Economic Times)
Roche Adds Manufacturing At NJ Site For Clinical Trials (New Jersey Star-Ledger)
Australia Adds Deferred Drugs To Benefits Program (Pharma Times)
EDITOR’S NOTE: Please check this post for updates throughout the morning
sunrise pic thx to benimoto on flickr
Leave a Comment
Subscribe
Comments feed for this post only.
Tags
Abbott Laboratories, AstraZeneca, Australia, Bayer, Contract Research Organization, CRO, Drug Shortages, Eli Lilly, Eraxix, FDA, GlaxoSmithKline, India, JJ, jobs, Johnson & Johnson, Layoffs, Medicaid, Michigan, New Jersey, Patents, Pfizer, PPD, Roche, Seroquel XR, Susan Desmond-Hellman, Vfend, Vioxx, Xarelto, Zyprexa